Publicaciones en las que colabora con Juan Carlos López Neila (18)

2014

  1. IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 21, Núm. 3, pp. 189-197

  2. PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: A cross-sectional study

    Journal of Translational Medicine, Vol. 12, Núm. 1

2013

  1. Association of torque teno virus (TTV) and torque teno mini virus (TTMV) with liver disease among patients coinfected with human immunodeficiency virus and hepatitis C virus

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 2, pp. 289-297

  2. European mitochondrial haplogroups are associated with CD41 T cell recovery in HIV-infected patients on combination antiretroviral therapy

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 10, pp. 2349-2357

  3. IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus

    Journal of Infection, Vol. 66, Núm. 2, pp. 170-178

  4. Prediction of hepatic fibrosis in patients coinfected with HIV and hepatitis C virus based on genetic markers

    Journal of Acquired Immune Deficiency Syndromes, Vol. 64, Núm. 5, pp. 434-442

2012

  1. High plasma CXCL10 levels are associated with HCV-genotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV/HCV coinfected patients

    Cytokine, Vol. 57, Núm. 1, pp. 25-29

  2. Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 5, pp. 1238-1245

2011

  1. European mitochondrial DNA haplogroups and liver fibrosis in HIV and hepatitis C virus coinfected patients

    AIDS, Vol. 25, Núm. 13, pp. 1619-1626

  2. European mitochondrial DNA haplogroups and metabolic disorders in HIV/HCV-coinfected patients on highly active antiretroviral therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 58, Núm. 4, pp. 371-378

  3. Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 30, Núm. 10, pp. 1213-1221

  4. Sustained virologic response decreases serum markers of angiogenesis, inflammation, and fibrosis in HIV/HCV-coinfected patients on hepatitis C virus therapy

    AIDS Patient Care and STDs

  5. Sustained virological response to interferon-α plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 3, pp. 645-649

2010

  1. CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients

    HIV Medicine, Vol. 11, Núm. 3, pp. 161-169

  2. Diagnosis of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new noninvasive index: The HGM-3 index

    HIV Medicine, Vol. 11, Núm. 1, pp. 64-73

  3. Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients

    AIDS, Vol. 24, Núm. 13, pp. 2059-2067

  4. Serum levels of adipokines in HIV/HCV co-infected patients and their association with insulin resistance and liver disease severity

    Journal of Infection

2009

  1. Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients?

    BMC Infectious Diseases, Vol. 10